CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Chemet (succimer) capsules — Coverage Criteria

Defines coverage and authorization criteria for Chemet (succimer) capsules for treatment of acute lead poisoning for Medicaid members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyChemet (succimer) capsules — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2022

Next Review DateN/A

Key ActionObtain prior authorization ensuring member is ≥12 months, has blood lead 45–69 mcg/L, therapy is for acute lead poisoning, and a chelation specialist is prescribing or consulted.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=12minimum member age

45-69blood lead level for approval

1 monthcoverage duration

requiredspecialist involvement

Coverage Criteria for Chemet (succimer) Capsules

The policy explicitly excludes use of Chemet (succimer) for prophylactic treatment in lead‑containing environments. Authorization is limited to treatment of acute lead poisoning only; requests for chelation intended solely to prevent lead absorption or as environmental prophylaxis do not meet the coverage criteria.

Use of Chemet (succimer) for prophylactic prevention of lead poisoning is considered not covered by the approval criteria. Only members meeting the documented diagnostic and laboratory thresholds for acute lead poisoning are eligible for authorization.

Coding and Clinical Thresholds

Covered medicationNDCCovered

Chemet (succimer) capsules

Drug name as covered medication per policy header

Covered medicationmixedCovered

Chemet (succimer) capsules

inv-05: Blood lead level — documented threshold required for approval.

Documented blood lead level45-69 mcg/L

PurposeEvidence of lead poisoning required — blood lead levels must be within the 45–69 mcg/L range for authorization

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyChemet (succimer) capsules — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2022

Next Review DateN/A

Key ActionObtain prior authorization ensuring member is ≥12 months, has blood lead 45–69 mcg/L, therapy is for acute lead poisoning, and a chelation specialist is prescribing or consulted.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required. Requests must meet all approval criteria and be submitted before medication initiation.

Authorization required when ALL approval criteria are met
Request must be submitted prior to initiation of therapy
Prescriber requirement: must be prescribed by or in consultation with a provider who specializes in chelation therapy (e.g., medical toxicologist or poison control specialist)

Documentation Required

Required Documentation

Provide documentation to support the prior authorization request. Include objective labs, diagnosis, age, and evidence of specialist involvement.

Member age (date of birth) showing ≥ 12 months
Diagnostic documentation of lead poisoning
Blood lead level results (evidence of lead level between 45–69 mcg/L)
Documentation of specialist consultation or that prescriber specializes in chelation therapy (e.g., medical toxicologist or poison control specialist)
Monitoring plan for liver and renal function (CBC with differential, LFTs, platelet count, serum creatinine/BUN)

Denial Risk

Denial Triggers

Requests will be denied if required criteria or documentation are missing or if use is outside of approved indications.

Missing required laboratory results (blood lead level)
Member younger than 12 months of age
Medication requested for prophylactic use in a lead-containing environment rather than for treatment of acute lead poisoning
No documented diagnosis of lead poisoning
No documentation of specialist involvement or consultation
No plan for routine monitoring of CBC, LFTs, platelets, and renal function

Note

Provider Action — Clinical Use and Monitoring

Ensure medication is prescribed for acute lead poisoning only and not for prophylaxis. Confirm monitoring and specialist oversight are documented.

Indication limited to acute lead poisoning
Confirm monitoring schedule and responsible clinician
Attach blood lead level results and specialist notes to the request

Background

Succimer (Chemet) is an oral chelating agent used to treat elevated blood lead levels. This policy governs coverage of Chemet capsules for the treatment of acute lead poisoning and requires documentation of member age and blood lead level thresholds prior to authorization. Key scope points: the member must be at least 12 months old, have a documented blood lead level in the range of 45–69 mcg/L, the medication must be prescribed by or in consultation with a provider who specializes in chelation therapy, and routine laboratory monitoring (CBC with differential, LFTs, platelet count, and serum creatinine/BUN) must be planned during therapy.

OpenPayer

Chemet (succimer) capsules — Coverage Criteria

Coverage Criteria for Chemet (succimer) Capsules

Coding and Clinical Thresholds

Provider Actions and Authorization

Definitions

Background